BioCryst Pharmaceuticals Q2 revenue rises, lifts 2026 revenue guidance

BioCryst Pharmaceuticals

05/08/2026 12:23

Overview
US biotechnology firm's Q2 revenue rose 34% yr/yr, driven by ORLADEYO and licensing revenue
Company posted Q2 operating profit of $98.5 mln, up from $29.8 mln a year ago
2026 total revenue guidance raised to $690 mln-$715 mln, ORLADEYO guidance maintained

Outlook
Company maintains 2026 global net ORLADEYO revenue guidance of $625 mln to $645 mln
BioCryst raises 2026 total revenue guidance to $690 mln to $715 mln
Company lowers 2026 non-GAAP operating expense outlook to $420 mln to $440 mln

Result Drivers
LICENSING REVENUE - Q2 revenue was boosted by $55.7 mln recognized from navenibart European licensing agreement
ORLADEYO SALES - ORLADEYO revenue rose 1% y-o-y, with stronger growth (+10% y-o-y) on a comparable basis excluding European revenue
PEDIATRIC LAUNCH - Initial shipments of ORLADEYO oral pellets for pediatric patients began in August, with strong prescription demand

Company press release: ID:nGNX7XG5N9

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
 
$0.30
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for BioCryst Pharmaceuticals, Inc. is $19.00, about 110.6% above its August 4 closing price of $9.02

Reuters Recommended Reads
Aug 4 - Ultragenyx Q2 revenue rises 28% to record high, net loss narrows
Aug 4 - Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand
Aug 3 - TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)